Xilio Therapeutics analyst ratings
Xilio Therapeutics analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2022 | 745.13% | Morgan Stanley | $32 → $20 | Maintains | Overweight |
| 01/10/2022 | 1421.23% | HC Wainwright & Co. | → $36 | Initiates Coverage On | → Buy |
| 11/16/2021 | 1209.95% | Raymond James | → $31 | Initiates Coverage On | → Outperform |
| 11/16/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/16/2021 | 1252.21% | Morgan Stanley | → $32 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/10/2022 | 745.13% | 摩根士丹利 | 32 美元 → 20 美元 | 维护 | 超重 |
| 2022 年 10 月 1 日 | 1421.23% | HC Wainwright & Co. | → 36 美元 | 启动覆盖范围开启 | → 购买 |
| 11/16/2021 | 1209.95% | 雷蒙德·詹姆 | → 31 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 11/16/2021 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
| 11/16/2021 | 1252.21% | 摩根士丹利 | → 32 美元 | 启动覆盖范围开启 | → 超重 |
Xilio Therapeutics Questions & Answers
Xilio Therapeutics 问题与解答
The latest price target for Xilio Therapeutics (NASDAQ: XLO) was reported by Morgan Stanley on August 10, 2022. The analyst firm set a price target for $20.00 expecting XLO to rise to within 12 months (a possible 745.13% upside). 5 analyst firms have reported ratings in the last year.
摩根士丹利于2022年8月10日公布了Xilio Therapeutics（纳斯达克股票代码：XLO）的最新目标股价。该分析公司将目标股价定为20.00美元，预计XLO将在12个月内升至12个月内（可能上涨745.13％）。去年有5家分析公司公布了评级。
The latest analyst rating for Xilio Therapeutics (NASDAQ: XLO) was provided by Morgan Stanley, and Xilio Therapeutics maintained their overweight rating.
摩根士丹利对Xilio Therapeutics（纳斯达克股票代码：XLO）的最新分析师评级由摩根士丹利提供，Xilio Therapeutics维持增持评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xilio Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xilio Therapeutics was filed on August 10, 2022 so you should expect the next rating to be made available sometime around August 10, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Xilio Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Xilio Therapeutics的最新评级是在2022年8月10日公布的，因此您应该预计下一个评级将在2023年8月10日左右公布。
While ratings are subjective and will change, the latest Xilio Therapeutics (XLO) rating was a maintained with a price target of $32.00 to $20.00. The current price Xilio Therapeutics (XLO) is trading at is $2.37, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Xilio Therapeutics（XLO）评级保持不变，目标股价为32.00美元至20.00美元。Xilio Therapeutics（XLO）目前的交易价格为2.37美元，超出了分析师的预期区间。